GILD vs BMY — Key Metrics
| Metric | GILD (GILEAD SCIENCES INC) | BMY (BRISTOL MYERS SQUIBB CO) |
|---|---|---|
| Price | 168.98 | 59.56 |
| Market Cap | 209.59 Billion | 121.75 Billion |
| P/E (TTM) | -54.51 | 13.15 |
| P/B (Quarterly) | 16.235 | 5.362 |
| P/S (TTM) | 6.76 | 2.43 |
| Net Profit Margin (TTM) | -12.5 | 18.5 |
| Gross Margin (TTM) | 79.9 | 69.2 |
| ROE (TTM) | -21.7 | 43.9 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Greatly Outperform
Recommendation Summary
Stock GILD is projected to outperform the market, stock BMY is projected to greatly outperform the market. Upfront Recommendation: BMY.
Financial Metrics
| GILD | Metrics | BMY |
|---|---|---|
| $168.98 | Price | $59.56 |
| — | Market Capitalization | — |
| 6.76 | Price to Sales | 2.43 |
| 15.21 | Price to FCF Ratio | 13.11 |
| 8.46 | Price to Gross Profit | 3.51 |
| 33.12 | Price to R&D | 11.53 |
| 12.66 | Price to Current Assets | 4.09 |
GILD vs BMY at a glance
Gilead Sciences INC (GILD) and Bristol Myers Squibb CO (BMY) are both Drug Manufacturers - General companies in the Healthcare sector. GILD is the larger, at $209.6 billion in market value against $121.7 billion for BMY, about 1.7 times the size.
On trailing-twelve-month figures, GILD trades at 6.8 times trailing sales and BMY at 2.4; net profit margins are -12.5% and 18.5%.
The Upfront Investment model currently rates GILD Outperform and BMY Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.